Envoy Medical, Inc. (COCHW) income statement

COCHWNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31Also trades as COCH

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026Score 5/30

$0.03−0.00 (-15.49%)

Close on Oct 30, 2026Market cap $511.80MP/E –Yield –

Envoy Medical, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	0.24	0.23	0.32	0.24	–
Cost of Revenue	0.87	0.74	0.79	0.50	–
Gross Profit	-0.63	-0.52	-0.47	-0.26	–
Research & Development	12	10	8.96	4.98	–
Selling, General & Admin	9.15	8.56	7.28	2.59	–
Selling & Marketing	1.22	1.73	1.67	0.89	–
General & Administrative	7.93	6.83	7.26	–	–
Total Costs & Expenses	23	19	19	8.94	–
Operating Income	-22	-19	-18	-8.71	-5.20
Interest Expense	1.59	0.82	–	–	–
Interest & Investment Income	–	–	–	6.13	0.04
Other Non-Operating Income	-1.49	-1.54	-12	-7.22	–
Asset Impairment Charges	–	0	–	–	–
Legal Settlements	-0.05	-0.05	-0.05	-0.05	–
Pretax Income	-24	-21	–	21	-0.25
Income Tax Expense	–	–	–	1.50	–
Net Income incl. Noncontrolling Interests	–	–	–	19	-0.25
Net Income	-24	-21	-30	-16	-0.25
Preferred Dividends	4.91	5.52	1.35	–	–
Net Income to Common	-29	-28	-31	-16	–
EPS (Basic)(per share)	-1.23	-1.49	-2.54	-1.57	–
EPS (Diluted)(per share)	-1.23	-1.49	-2.54	-1.57	–
Shares Outstanding (Basic, Weighted)(shares)	23	19	12	10	–
Shares Outstanding (Diluted, Weighted)(shares)	23	19	12	10	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: -385.5%
Operating margin: -11411.1%
Net margin: -11304.8%
Return on equity, FY2025: 153.3%

Financial strength

Current ratio: 1.73
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 155.8%

Valuation

P/E ratio: –
Price to sales: 2472.46
Price to book: 154.95
Dividend yield: –